KMDA vs GRFS vs CSL vs BIO vs BRKR

For growth investors, Kamada Ltd.

(KMDA) is the stronger pick with 21. 4% revenue growth year-over-year, versus 0. 2% for Grifols, S. A. (GRFS). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 2x trailing P/E (25. 0x forward), making it the more compelling value choice. Analysts rate Kamada Ltd. (KMDA) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bio-Rad Laboratories, Inc.

(BIO) is the cheapest at 9. 2x versus Kamada Ltd. at 22. 3x. On forward P/E, Grifols, S. A. is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Carlisle Companies Incorporated (CSL) delivered a total return of +95.

1%, compared to -57. 7% for Bio-Rad Laboratories, Inc. (BIO). Over 10 years, the gap is even starker: CSL returned +277. 4% versus GRFS's -35. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Rad Laboratories, Inc.

(BIO) is the lower-risk stock at 0. 92β versus Bruker Corporation's 1. 59β — meaning BRKR is approximately 72% more volatile than BIO relative to the S&P 500. On balance sheet safety, Kamada Ltd. (KMDA) carries a lower debt/equity ratio of 4% versus 160% for Carlisle Companies Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Kamada Ltd.

(KMDA) is pulling ahead at 21. 4% versus 0. 2% for Grifols, S. A. (GRFS). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -119. 7% for Bruker Corporation. Over a 3-year CAGR, KMDA leads at 14. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus -0. 3% for Bruker Corporation — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CSL leads at 19. 9% versus 6. 9% for BRKR. At the gross margin level — before operating expenses — BIO leads at 52. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Grifols, S.

A. (GRFS) trades at 9. 2x forward P/E versus 25. 0x for Bio-Rad Laboratories, Inc. — 15. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KMDA: 45. 3% to $12. 00.

In this comparison, GRFS (2.

6% yield), KMDA (2. 6% yield), CSL (1. 2% yield), BRKR (0. 3% yield) pay a dividend. BIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Carlisle Companies Incorporated (CSL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

12), 1. 2% yield, +277. 4% 10Y return). Bruker Corporation (BRKR) carries a higher beta of 1. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CSL: +277. 4%, BRKR: +67. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (KMDA (Healthcare) and GRFS (Healthcare) and CSL (Industrials) and BIO (Healthcare) and BRKR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: KMDA is a small-cap high-growth stock; GRFS is a small-cap deep-value stock; CSL is a mid-cap quality compounder stock; BIO is a small-cap deep-value stock; BRKR is a small-cap quality compounder stock. KMDA, GRFS, CSL pay a dividend while BIO, BRKR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.